Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2015-03-27 Regulatory Filings
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2015
Regulatory Filings
2015-03-27 English
RANDAL J KIRK SC 13D 3-16-2015 (AMPLIPHI BIOSCIENCES CORP)
Major Shareholding Notification
2015-03-20 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. The content describes a private placement of equity securities, including details about the subscription agreement, shares issued, warrants, and registration rights. It includes exhibits related to the subscription agreement and warrants. The document is an announcement of a capital raising event and related agreements, not a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 4326 characters, which is consistent with a typical 8-K filing for such an event.
2015-03-19 English
FORM 4
Director's Dealing
2015-03-18 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 10, 2015. It announces that AmpliPhi Biosciences Corporation entered into definitive agreements for a private placement financing to raise approximately $13 million. The document includes a press release as an exhibit. The content focuses on a financing event, specifically a private placement of common stock and warrants. There are no financial statements or detailed financial analysis included, only an announcement of the financing transaction. According to the filing definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP). The document length is 2761 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is CAP with high confidence.
2015-03-11 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The content specifically discusses the Audit Committee's determination that previously issued financial statements for certain fiscal periods need to be restated due to errors identified in non-cash items. It mentions plans to file amended 10-K and 10-Q forms. The document does not contain the full restated financial statements or detailed financial data itself but rather announces the restatement and related actions. The document length is 3085 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), as it is a regulatory announcement about restatements and amended filings, not the restated reports themselves.
2015-03-06 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.